Smith B D, Bao T, Karp J E
Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA.
J Biol Regul Homeost Agents. 2005 Jan-Jun;19(1-2):23-32.
Acute myeloid leukemia (AML) and myelodysplasia (MDS) continue to present formidable treatment challenges as there is not yet a "standard approach" that reliably and safely cures the majority of adults with these disorders. Understanding the basic cellular and molecular biology of leukemia is vital to the development of better treatment approaches. All malignant cells, including leukemias, carry survival advantages compared to their normal counterparts. These survival advantages are particularly evident when the cells face both normal environmental stressors as well as extreme stressors of potentially lethal DNA damage. The impact of such stressors is ultimately determined by the signaling pathways and resultant cellular activation, including alterations in cellular growth, differentiation, survival and death. It is our improving understanding of these signaling pathways, both normal and malignant, that provide the targets for novel therapies. In this review article, we will focus on several signaling pathways, as well as the regulation of the cell cycle, that not only represent potentially accessible sites for intervention in myeloid malignancies, but those that are actively being studied.
急性髓系白血病(AML)和骨髓增生异常综合征(MDS)仍然带来巨大的治疗挑战,因为目前尚无一种能可靠且安全地治愈大多数患有这些疾病的成年人的“标准方法”。了解白血病的基本细胞和分子生物学对于开发更好的治疗方法至关重要。所有恶性细胞,包括白血病细胞,与它们的正常对应细胞相比都具有生存优势。当细胞面临正常环境应激源以及潜在致死性DNA损伤的极端应激源时,这些生存优势尤为明显。此类应激源的影响最终由信号通路及由此产生的细胞活化决定,包括细胞生长、分化、存活和死亡的改变。正是我们对这些正常和恶性信号通路的不断深入理解为新型疗法提供了靶点。在这篇综述文章中,我们将聚焦于几个信号通路以及细胞周期的调控,这些不仅代表了髓系恶性肿瘤中潜在可干预的位点,而且是目前正在积极研究的位点。